William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sami Corwin has given his Buy rating due to a combination of factors that highlight the promising potential of Solid Biosciences’ SGT-003 therapy. The updated data from the Phase I/II INSPIRE DUCHENNE trial indicates competitive levels of microdystrophin expression, which is a key biomarker for muscle preservation. Notably, the expression levels were maintained in patients over time, showcasing the therapy’s potential durability and efficacy. Additionally, strong correlations between microdystrophin expression and improvements in other muscle preservation markers further support the therapy’s promise.
Sami Corwin’s rating is also influenced by the potential cardiac benefits of SGT-003, as evidenced by the normalization of left ventricle ejection fraction and significant reductions in serum cardiac troponin I levels. The therapy has shown a favorable safety profile, with no cases of drug-induced liver injury and manageable adverse events. With plans to engage with the FDA and the initiation of a Phase III trial, Solid Biosciences is positioned for significant progress, justifying the Buy rating.
In another report released today, Chardan Capital also maintained a Buy rating on the stock with a $15.00 price target.